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Abstract
Objective
To develop a disease activity index for patients with primary Sj gren s syndrome (SS): the European League Against Rheumatismö ’
(EULAR) Sj gren s Syndrome Disease Activity Index (ESSDAI).ö ’
Methods
Thirty-nine SS experts participated in an international collaboration, promoted by EULAR, to develop the ESSDAI. Experts
identified 12 organ-specific domains  contributing to disease activity. For each domain, features of disease activity were classified in 3“ ”
or 4 levels according to their severity. Data abstracted from 96 patients with systemic complications of primary SS were used to
generate 702 realistic vignettes for which all possible systemic complications were represented. Using the 0 10 physician global–
assessment (PhGA) scale, each expert scored the disease activity of 5 patient profiles and 20 realistic vignettes. Multiple regression
modelling, with PhGA used as the dependent variable, was used to estimate the weight of each domain.
Results
All 12 domains were significantly associated with disease activity in the multivariate model, domain weights ranged from 1 to 6. The
ESSDAI scores varied from 2 to 47 and were significantly correlated with PhGA for both real patient profiles and realistic vignettes
(r 0.61 and r 0.58, respectively, p<0.0001). Compared to 57 (59.4 ) of the real patient profiles, 468 (66.7 ) of the realistic vignettes= = % %
were considered likely or very likely to be true.
Conclusion
The ESSDAI is a clinical index designed to measure disease activity in patients with primary SS. Once validated, such a standardized
evaluation of primary SS should facilitate clinical research and should be helpful as an outcome measure in clinical trials.
Author Keywords primary Sjogren s syndrome ' ; outcome assessment ; systemic features ; activity index ; clinical vignettes ; disease activity
Primary Sj gren s syndrome (SS) is a systemic disorder characterized by lymphocytic infiltration and progressive destruction ofö ’
exocrine glands. The inflammatory process can, however, affect any organ. As a result, clinical features can be divided into two facets: (i)
benign but disabling manifestations such as dryness, pain and fatigue, affecting almost all patients; and (ii) severe systemic manifestations
that affect 20  to 40  of patients.% %
Evidence-based therapy for SS is largely limited to treatments that improve sicca features.  Clinical trials of disease-modifying[1 ]
therapies have used a variety of ad hoc outcome measures mainly based on glandular features or patient symptoms, but not systemic
features.  Valid activity indexes are needed  to assess the effectiveness of new targeted therapies, such as B-cell targeted[2 –6 ] [7 –9 ]
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therapies that have shown promising results for both severe systemic ,  and glandular features.  Two disease activity[10 11 ] [12 –15 ]
indexes have recently been proposed: the SS disease activity index (SSDAI)  and the Sj gren s Systemic Clinical Activity Index[16 ] ö ’
(SCAI).  The development of these indexes was based on exploratory studies conducted in single countries, but they serve as the basis[17 ]
of the present collaborative project. Thus, the European League Against Rheumatism (EULAR) has promoted an international
collaboration to develop consensus disease activity indexes. Two indices are currently in development: (i) a patient-administered
questionnaire to assess patient symptoms, the EULAR Sj gren s Syndrome Patient Reported Index (ESSPRI); and (ii) a systemic activityö ’
index to assess systemic complications, the EULAR Sj gren s Syndrome Disease Activity Index (ESSDAI).ö ’
We now describe the development and initial validation of the ESSDAI. This index was developed with the help of a worldwide panel
of primary SS experts using physician global assessment (PhGA) of disease activity as an external criterion. The aim is for the ESSDAI to
be used as outcome criteria to evaluate primary SS in a standardized way in both clinical trials and daily practice.
METHODS
This paper results from a collaboration of experts identified through their involvement in the primary SS field, headed by a steering
committee of 7 physician experts in SS (HB, SB, JEG, XM, ET, AT, CV), a clinical epidemiologist (PR) and a rheumatologist, a fellow in
clinical epidemiology (RS). The research protocol was endorsed by EULAR ( ).project code CLI 010 
The steps of the development of the ESSDAI are summarized below; the entire methodology is available online ( ).Appendix 1 
Selection of relevant domains and definition of items
Domains of organ-specific involvement relevant to assess disease activity were selected in these steps. For each domain, the different
clinical manifestations were ranked by level of activity (i.e., items). For selection of domains relevant to disease activity and definition of
items for each domain, steering committee members prepared a preliminary proposal on the basis of their clinical experience, literature
review and previous work. ,  The preliminary selection of domains and items were successively submitted to the expert panel.[16 17 ]
Experts had to rate the importance of each domain or suggest any additional domains or changes to proposed items. Intention-to-treat was
used as a help for experts to define the different activity levels that ranged from no activity (requiring no treatment) to high activity
(requiring high dose steroids or immunosuppressant). The experts  proposals were analyzed, then discussed and voted on during a meeting.’
Elaboration of clinical vignettes
In this step, realistic clinical vignettes were generated from real patient profiles.
Abstraction and standardization of real patient profiles
Five members of the steering committee supplied 96 profiles of their patients with systemic complications of primary SS. Each profile
had to contain sections on History  (demographic data and past medical history), Today  (clinical symptoms and results of imaging“ ” “ ”
examination) and Laboratory  (biological features). Patient profiles included data from the baseline and 2 follow-up visits (3 and 6“ ”
months).
Abstraction of descriptions of items from real patient profiles
From patient profiles, 96 histories and 364 items, included in the Today  and Laboratory  sections, were extracted and standardized“ ” “ ”
by the same investigator (RS). Description of all ESSDAI items were obtained and entered in a database with their corresponding scoring
(domain and activity level). Each item had a median of 8.5 (interquartile range IQR: 4 15  descriptions.[ – ]
Generation of realistic clinical vignettes
Determination of construction rules
Data from primary SS patient cohorts of 5 members of the steering committee (SB, XM, ET, AT, CV)  were used to construct[16 –20 ]
a sample of vignettes with characteristics similar to European patient cohorts.
Generation of clinical vignettes
In total, 720 clinical vignettes were generated by a combination of History  and items from the Today  and Laboratory  sections,“ ” “ ” “ ”
with respect to the domain and item distribution defined previously. However, because items in the database referred to only systemic
features, descriptors of symptoms such as dryness, pain and fatigue were generated and assigned to 30  of the patient vignettes.%
Assessment
The 96 real patient profiles and the 720 clinical vignettes were randomly assigned to the 40 experts. Each expert had to rate 5 real
patient profiles (rated by 2 raters each) and 20 clinical vignettes (18 were unique  and 2 were common  to 2 raters). For the survey, an“ ” “ ”
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internet-secure relational database was constructed. Patient data were presented chronologically, and the responses could not be changed.
For all visits of each profile or vignette, experts had to assess disease activity by use of the PhGA on a 0 10 numerical scale and a 5-point–
scale (inactive, low, moderate, high, very high activity). For the first visit of each profile or vignette, they also had to evaluate the
plausibility of each patient case with use of a 5-point scale (very unlikely, unlikely, possible, likely, very likely) by answering the
following question: Please indicate, according to your clinical experience and knowledge of the disease, the likelihood that this patient“
scenario is a real case .”
Statistical methods
Determination of domain weights and construction of the ESSDAI
Realistic clinical vignettes were used to determine domain weights. Disease activity assessed by the PhGA was used as an external
criterion. Bivariate analysis involved Pearson s correlation between PhGA and each domain separately; for each domain, scores ranged’
from 0  no activity  to 3  high activity . All domains were entered into multivariate models; the PhGA was used as a dependant= “ ” = “ ”
variable and each domain was an explanatory variable. Two models were evaluated: a multiple linear regression model and a robust
regression model with the least-median-of-squares method with an MM estimator. ,  The weights assigned to each domain were[21 22 ]
derived from the regression coefficients of the multivariate model and rounded to form simplified indices. The weight of each item was
obtained by multiplying the weight of the domain by the level of activity.
Preliminary validation
The ESSDAI was then calculated for all real patient profiles and realistic clinical vignettes. Construct validity was assessed by the
strength of correlation between the ESSDAI score and the disease activity score assigned by the expert.
Sensitivity analyses
To evaluate the stability/robustness of the domain weight estimation, other models were tested: a logistic regression model with the
5-point scale used as an external criterion and different multiple linear regression models after pooling items that clustered.
Patient profile plausibility
Evaluation of patient profile plausibility of realistic clinical vignettes was compared to that of real patient profiles by a
Cochran-Armitage trend test.
Reliability of disease activity scoring
The evaluation of clinical vignettes common to 2 raters was used to assess inter-rater reliability:
For the 0 10 PhGA: intraclass correlation coefficient (ICC) and Bland and Altman graphical analysis , – [23 24 ]
For the 5-point scale: global agreement and Kappa statistics , [25 26 ]
The evaluation of real patient profiles was used to assess intra-rater reliability by the ICC, if at the first follow-up visit, the physician
considered the disease activity unchanged. ICC confidence intervals were estimated with bootstrapping methods, with 1000 replications.[
27 ]
For all statistical analyses, a p-value less than 0.05 was considered statistically significant. All statistical analyses involved use of SAS
release 9.1 and R release 2.2.1 statistical software packages.
RESULTS
Characteristics of expert panel
Of 40 invited primary SS experts, 39 took part in the study (35 Europeans from 13 countries and 4 North Americans). The median age
of experts was 49 IQR: 46 58  years; 35 were rheumatologists, 3 were internists and 1 was an oral medicine practitioner. All but 2 (94.9[ – ] %
) had 10 years of experience in managing primary SS. All were involved in clinical research, and 23 (59.0 ) were also involved in basic≥ %
science research into primary SS.
Selection of domains and definition of items
All 10 domains (constitutional and lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, muscular, peripheral nervous
system, central nervous system, hematological) proposed by the steering committee were included. Experts decided to divide the “
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constitutional and lymphadenopathy  domain into 2 domains and to add a biological domain but not add a hepatic domain (considered to”
result from damage). The definition of the different activity levels (items) of each domain was obtained by consensus after discussion
during meetings of the steering committee and experts.
Characteristics of real patient profiles and realistic vignettes
Thirty-nine of the 40 experts completed the rating of the 96 real patient profiles and 702 of the 720 clinical vignettes ( ). RealTable 1 
patient profiles, selected for the extent of systemic involvement, had a significantly higher number of involved organs than did realistic
clinical vignettes (2.83  1.46 vs. 2.14  1.08; p<0.0001).± ±
Determination of domain weights and derivation of the ESSDAI
All domains, except haematological, glandular, articular and biological domains, showed a significant positive correlation with PhGA
score ( ). All domains were entered in 2 multivariate regression models. Multiple linear and least-median-of-squares regressionTable 2 
models provided similar results (R 0.29 and R 0.30, respectively). In both models, all domains were significantly associated with2 = 2 =
disease activity (PhGA), and the weight estimation was similar. The weights derived from the regression coefficients were rounded to
obtain a simple index ( and ).Tables 2 3 
Preliminary validation of the ESSDAI in real patient profiles and realistic vignettes
The mean ESSDAI scores were 15.48 9.16 and 9.04 6.43 for real patient profiles and realistic vignettes, respectively. ESSDAI scores± ±
were significantly correlated with the PhGA score (r 0.58 for realistic vignettes and r 0.61 for real patient profiles, p<0.0001; ).= = Figure 1 
The maximum theoretical ESSDAI score is 123; however, only 25  of realistic vignettes and the real patient profiles had a score 13 and % ≥
21, respectively. The highest score was 42 and 47 for the realistic vignettes and real profiles, respectively ( ).≥ Figure 1 
Sensitivity analyses
Other models for testing sensitivity analyses led to similar domain weights and similar correlation with the PhGA score.
Patient profile plausibility
Overall, experts considered 468 (66.7 ) of the 702 vignettes likely or very likely to be true, as compared with 57 (59.4 ) of the 96% %
real patient profiles (p 0.09).=
Reliability of disease activity scoring
Inter-rater reliability assessed by the ICC on 76 common vignettes was 0.41 0.18 0.60  for the PhGA. Bland and Altman graphical[ – ]
analysis revealed no systematic errors (mean difference 0.16) but a variability of rating among experts (95  agreement interval 4.92 to=− % [−
4.61 ). The ratings of the same vignette by 2 different experts differed by 1 point for 37 vignettes (48.7 ), by 2 to 3 points for 30 (39.5+ ] ≤ %
), and by >3 points for 9 (11.8 ). The weighted Kappa statistic for disease activity rating by the 5-point scale was 0.32 0.18 0.47 .% % [ – ]
When grouping the highest activity scores (high and very high activity) and the lowest scores (inactive, low and moderate activity), the
observed agreement was 72.4  and the Kappa coefficient 0.42 0.21 0.63 .% [ – ]
Intra-rater reliability of the PhGA for 20 real patient profiles with unchanged activity at the first follow-up visit as assessed with the
ICC was 0.86 0.68 0.94 .[ – ]
DISCUSSION
The ESSDAI is a consensus clinical index designed to measure disease activity in patients with systemic complications of primary SS.
This index is modelled on physician s judgment of disease activity. It results from a large collaboration of European and North American’
experts in primary SS. Compared to the PhGA, the ESSDAI performed satisfactorily for evaluation of disease activity in primary SS.
In the absence of an available gold standard  or true understanding of disease process, the most accurate and meaningful method of“ ”
disease activity assessment is to attempt to model the physician judgment. But any scale quantifying physician judgment of disease activity
is a simplification of a complex mental process. For that purpose, 2 main gold standards have been used in the development of disease
activity indexes: (i) the PhGA  and (ii) the intention-to-treat approach. ,  The PhGA was used for the development of the[28 –30 ] [31 32 ]
systemic lupus disease activity index (SLEDAI) in systemic lupus erythematosus (SLE),  whereas the intention-to-treat approach[28 –30 ]
was used for the development of the British Isles lupus assessment group (BILAG) for SLE  and the disease activity score (DAS) for[31 ]
rheumatoid arthritis (RA).  However, unlike RA that quasi-exclusively affects articular system and where therapeutic decision is[32 ]
reproducible, the multisystemic nature of primary SS make therapeutic decision more variable. In addition, evidence-based therapeutic
management of SLE is currently more advanced than in primary SS. Moreover, in the BILAG, this approach was used to define, in each
domain, the different classes (A, B, C, D, E) and not as gold standard  to determine domain weights. Therefore, in the absence of effective“ ”
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treatment or consensual therapeutic management and because of the variability of physician habits, the intention-to-treat approach might
be more difficult to apply as a gold standard for primary SS at this time.
In addition, the extent to which each organ involvement or patient symptoms of fatigue and pain can influence the physician s’
evaluation of disease activity, in such a polymorphous disease, is extremely variable, as demonstrated by the limited reliability of the
PhGA. These discrepancies among physicians  views, even among disease experts, justify the necessity for a more objective and’
standardized scoring system to homogenise assessment of disease activity in different settings, by different physicians, experts but also less
experienced physicians. Similar to correlation of SCAI scores with the PhGA,  that of ESSDAI scores with the PhGA was about 0.60.[17 ]
These correlations were lower than that from other studies evaluating disease activity scores for various systemic disorders , , .[16 29 33 ]
However, in most of these studies, the experts involved were trained to the rating of the PhGA and the different activity tools to improve
reliability and homogeneity of this scoring. In the present study, to be closer to usual practice, we decided not to perform a training
exercise.
The ESSDAI was developed by a large panel of primary SS experts and attempted to reflect their thought process. This may have
ensured the content validity of the ESSDAI, including all relevant determinants of disease activity. The validity of the ESSDAI was further
confirmed by the significant association of all domains with disease activity in our model. Previous primary SS activity indexes have been
developed with use of cohorts in which about half of the patients had inactive or weakly active disease. ,  Our strategy was to use[16 17 ]
data from selected patients with systemic features to generate realistic clinical vignettes. This methodology enabled us to obtain a large
number of vignettes (more than would have been possible with real patients) representing all possible systemic disease involvement (i.e.,
items). We then evaluated the extent to which each item influenced the evaluation of disease activity, which had not been possible in
previous studies that did not include all organ-specific features. ,  As in all global scoring system, ,  similar ESSDAI scores[16 17 ] [16 29 ]
(same disease activity) may reflect different domains involved. As a further component of this project we will also be evaluating the most
common patient-reported symptoms such as dryness, pain and fatigue in a patient-completed questionnaire the ESSPRI.
A major challenge in designing a systemic index is distinguishing between damage and disease activity. The most frequent approach,
to avoid scoring damage, is to consider manifestations as active only if new  or worsening.  Under these scoring systems, when patients“ ” “ ”
are evaluated at two time points, a persistent manifestation will not be rated at the second time point, which may cause an erroneous
interpretation of improvement even though the patient s condition has not changed. To avoid this, all ESSDAI items were defined without’
reference to a previous assessment, but with an advice not to rate as active stable long-lasting features related to damage.
The ESSDAI is a systemic disease activity index developed to allow a standardized evaluation of disease activity in primary SS
patients. Further studies are needed to assess the reliability and sensitivity to change of the ESSDAI. Once validated, if uniformly applied,
the ESSDAI might enable comparison between studies and facilitate clinical research into primary SS. After the development of the
patient-completed questionnaire (ESSPRI), the use of both the ESSDAI and ESSPRI for outcome assessment in randomized controlled
trials should allow for assessing all facets of the disease.
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Figure 1
Distribution of ESSDAI scores and correlation with disease activity in real patient profiles and realistic vignettes
Figures 2A, 2B, 2C refer to the 702 realistic clinical vignettes, and figures 2D, 2E, 2F refer to the 96 real patient profiles. Distribution of
ESSDAI scores in realistic vignettes (A) and real patient profiles (D), ESSDAI score for each level of global activity as defined by physicians
on the 5-point scale (B and E), and correlation between ESSDAI scores and physicians  ratings of disease activity by the physician global’
assessment (PhGA) scale (0 10 scale) (C and F). – For box plots of ESSDAI scores, the boxes represent the 25th and 75th percentiles; the lines
within the box represent the median; the dot inside the box, linked by a line, represents the mean; and the whiskers extend to the most extreme
data point, which is no more than 1.5 times the interquartile range (difference between the 75th and 25th percentiles) from the box. Values
that are more extreme were considered outliers and are plotted individually (dots).
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Table 1
Demographic characteristics for the 96 real patient profiles and 702 realistic clinical vignettes.
Real patient profiles (n 96)= Realistic clinical vignettes (n 702)=
Age 55.92 15.13± 55.85 14.21±
Female sex 89 (92.71 )% 647 (92.17 )%
Disease duration 8.58 7.25± 8.46 7.04±
Oral dryness 90 (93.75% 641 (91.31 )%
Ocular drynes 82 (85.42% 599/697 (85.94 )%
Objectively assessed drynes 63/63(100 )% 456/456 (100 )%
Anti-SSA antibodies 82 (86.42 )% 595 (84.76 )%
Anti-SSB antibodies 56 (58.33 )% 399 (56.84 )%
Lymphocytic sialadenitis with focus score 1≥ 70/74 (94.59 )% 490/525 (93.33 )%
Organ involvement
 Constitutional symptoms 14 (14.58 )% 76 (10.83 )%
 Lymphadenopathy 9 (9.38 )% 80 (11.40 )%
 Lymphoma 8 (8.33 )% 35 (4.99 )%
 Glandular 27 (28.12 )% 270 (38.46 )%
 Articular 36 (37.5 )% 396 (56.14 )%
 Cutaneous 29 (30.21 )% 74 (10.54 )%
 Pulmonary 22 (22.92 )% 90 (12.82 )%
 Renal 14 (14.58 )% 37 (5.27 )%
 Muscular 2 (2.08 )% 22 (3.13 )%
 Peripheral nervous system 15 (15.62 )% 64 (9.12 )%
 Central nervous system 7 (7.29 )% 20 (2.85 )%
 Hematological 25 (26.04 )% 72 (10.26 )%
 Biological markers of B-cell activation 64 (66.67 )% 268 (38.18 )%
Data are presented as number ( ) or mean SD.% ±
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Table 2
Correlation between domains and disease activity, as assessed by the physician global assessment (PhGA) scale, and regression coefficients and domain weights obtained with the least-median-of-squares
robust regression model with an MM estimator.
Domains
Bivariate analysis Multivariate modelling Least median of square with MM estimator
Correlation with PhGA p-value Regression coefficient Standard error Weight p-value
Constitutional 0.106 0.005 0.704 0.163 3 <0.0001
Lymphadenopathy 0.134 0.0004 0.817 0.089 4 <0.0001
Glandular 0.067 0.078 0.407 0.091 2 <0.0001
Articular 0.063 0.095 0.489 0.068 2 <0.0001
Cutaneous 0.156 <0.0001 0.559 0.097 3 <0.0001
Pulmonary 0.170 <0.0001 1.066 0.115 5 <0.0001
Renal 0.125 0.0009 1.090 0.170 5 <0.0001
Muscular 0.156 <0.0001 1.193 0.191 6 <0.0001
PNS 0.197 <0.0001 0.944 0.117 5 <0.0001
CNS 0.159 <0.0001 0.936 0.157 5 <0.0001
Hematological 0.041 0.277 0.361 0.126 2 0.004
Biological 0.073 0.053 0.206 0.080 1 0.010
PhGA  physician global assessment; PNS  peripheral nervous system; CNS  central nervous system.= = =
For bivariate analysis, Pearson s correlation coefficient (r) were obtained between PhGA and each domain; for each domain, scores ranged from 0  no activity  to 3  high activity . All domains were’ = “ ” = “ ”
entered in multivariate regression with the least-median-of-squares model with an MM estimator. R 0.30 for the model. All domains were significantly associated with disease activity (as defined by2 =
the 0 10 PhGA numerical scale) in the multivariate model. The weights were derived from the regression coefficient of the multivariate model.–
Table 3





Exclusion of fever of infectious origin and
voluntary weight loss
No  0= Absence of the following symptoms
Low  1= Mild or intermittent fever (37.5 38.5 C)/night sweats and/or involuntary weight loss of 5 to 10  of body weight°– ° %
Moderate
 2=
Severe fever (>38.5 C)/night sweats and/or involuntary weight loss of >10  of body weight° %
Lymphadenopathy [4 ]
Exclusion of infection
No  0= Absence of the following features
Low  1= Lymphadenopathy  1 cm in any nodal region or  2 cm in inguinal region≥ ≥
Moderate
 2=
Lymphadenopathy  2 cm in any nodal region or  3 cm in inguinal region, and/or splenomegaly (clinically palpable or assessed by imaging)≥ ≥
High  3= Current malignant B-cell proliferative disorder
Glandular [2 ]
Exclusion of stone or infection
No  0= Absence of glandular swelling
Low 1= Small glandular swelling with enlarged parotid (  3 cm), or limited submandibular or lachrymal swelling≤
Moderate
 2=
Major glandular swelling with enlarged parotid (> 3 cm), or important submandibular or lachrymal swelling
Articular [2 ]
Exclusion of osteoarthritis
No  0= Absence of currently active articular involvement
Low  1= Arthralgias in hands, wrists, ankles and feet accompanied by morning stiffness (>30 min)
Moderate
 2=
1 to 5 (of 28 total count) synovitis
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High  3= ≥ 6 (of 28 total count) synovitis
Cutaneous [3 ]
Rate as No activity  stable long-lasting features“ ”
related to damage
No  0= Absence of currently active cutaneous involvement
Low 1= Erythema multiforma
Moderate
 2=
Limited cutaneous vasculitis, including urticarial vasculitis, or purpura limited to feet and ankle, or subacute cutaneous lupus
High  3= Diffuse cutaneous vasculitis, including urticarial vasculitis, or diffuse purpura, or ulcers related to vasculitis
Pulmonary [5 ]
Rate as No activity  stable long-lasting features“ ”
related to damage, or respiratory involvement not
related to the disease (tobacco use etc.)
No 0= Absence of currently active pulmonary involvement
Low  1= Persistent cough or bronchial involvement with no radiographic abnormalities on radiography
Or radiological or HRCT evidence of interstitial lung disease with: No breathlessness and normal lung function test.
Moderate
 2=
Moderately active pulmonary involvement, such as interstitial lung disease shown by HRCT with shortness of breath on exercise (NHYA II) or
abnormal lung function tests restricted to: 70  >DL  40  or 80 >FVC 60% CO ≥ % % ≥ %
High  3= Highly active pulmonary involvement, such as interstitial lung disease shown by HRCT with shortness of breath at rest (NHYA III, IV) or with
abnormal lung function tests: DL < 40  or FVC< 60CO % %
Renal [5 ]
Rate as No activity  stable long-lasting features“ ”
related to damage, and renal involvement not
related to the disease.
If biopsy has been performed, please rate activity
based on histological features first
No  0= Absence of currently active renal involvement with proteinuria< 0.5 g/d, no hematuria, no leucocyturia, no acidosis, or long-lasting stable proteinuria
due to damage
Low  1= Evidence of mild active renal involvement, limited to tubular acidosis without renal failure or glomerular involvement with proteinuria (between 0.5
and 1 g/d) and without hematuria or renal failure (GFR 60 ml/min)≥
Moderate
 2=
Moderately active renal involvement, such as tubular acidosis with renal failure (GFR <60 ml/min) or glomerular involvement with proteinuria
between 1 and 1.5 g/d and without hematuria or renal failure (GFR 60 ml/min) or histological evidence of extra-membranous glomerulonephritis or≥
important interstitial lymphoid infiltrate
High  3= Highly active renal involvement, such as glomerular involvement with proteinuria >1.5 g/d or hematuria or renal failure (GFR <60 ml/min), or
histological evidence of proliferative glomerulonephritis or cryoglobulinemia related renal involvement
Muscular [6 ]
Exclusion of weakness due to corticosteroids
No  0= Absence of currently active muscular involvement
Low  1= Mild active myositis shown by abnormal EMG or biopsy with no weakness and creatine kinase (N <CK  2N)≤
Moderate
 2=
Moderately active myositis proven by abnormal EMG or biopsy with weakness (maximal deficit of 4/5), or elevated creatine kinase (2N<CK 4N),≤
High  3= Highly active myositis shown by abnormal EMG or biopsy with weakness (deficit  3/5) or elevated creatine kinase (>4N)≤
PNS [5 ]
Rate as No activity  stable long-lasting features“ ”
related to damage or PNS involvement not related
to the disease
No  0= Absence of currently active PNS involvement
Low  1= Mild active peripheral nervous system involvement, such as pure sensory axonal polyneuropathy shown by NCS or trigeminal (V) neuralgia
Moderate
 2=
Moderately active peripheral nervous system involvement shown by NCS, such as axonal sensory-motor neuropathy with maximal motor deficit of
4/5, pure sensory neuropathy with presence of cryoglobulinemic vasculitis, ganglionopathy with symptoms restricted to mild/moderate ataxia,
inflammatory demyelinating polyneuropathy (CIDP) with mild functional impairment (maximal motor deficit of 4/5or mild ataxia),
Or cranial nerve involvement of peripheral origin (except trigeminal (V) neralgia)
High  3= Highly active PNS involvement shown by NCS, such as axonal sensory-motor neuropathy with motor deficit 3/5, peripheral nerve involvement due≤
to vasculitis (mononeuritis multiplex etc.), severe ataxia due to ganglionopathy, inflammatory demyelinating polyneuropathy (CIDP) with severe
functional impairment: motor deficit 3/5 or severe ataxia≤
CNS [5 ]
Rate as No activity  stable long-lasting features“ ”
related to damage or CNS involvement not related
to the disease
No  0= Absence of currently active CNS involvement
Low  1= Moderately active CNS features, such as cranial nerve involvement of central origin, optic neuritis or multiple sclerosis-like syndrome with symptoms
restricted to pure sensory impairment or proven cognitive impairment
High  3= Highly active CNS features, such as cerebral vasculitis with cerebrovascular accident or transient ischemic attack, seizures, transverse myelitis,
lymphocytic meningitis, multiple sclerosis-like syndrome with motor deficit.
Hematological [2 ]
For anemia, neutropenia, and thrombopenia, only
auto-immune cytopenia must be considered
No  0= Absence of auto-immune cytopenia
Low  1= Cytopenia of auto-immune origin with neutropenia (1000 < neutrophils < 1500/mm3), and/or anemia (10 < hemoglobin < 12 g/dl), and/or
thrombocytopenia (100,000 < platelets < 150,000/mm3)
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Exclusion of vitamin or iron deficiency,
drug-induced cytopenia
Or lymphopenia (500 < lymphocytes < 1000/mm3)
Moderate
 2=
Cytopenia of auto-immune origin with neutropenia (500  neutrophils  1000/mm3), and/or anemia (8  hemoglobin  10 g/dl), and/or≤ ≤ ≤ ≤
thrombocytopenia (50,000  platelets  100,000/mm3)≤ ≤
Or lymphopenia ( 500/mm3)≤
High  3= Cytopenia of auto-immune origin with neutropenia (neutrophils < 500/mm3), and/or or anemia (hemoglobin < 8 g/dl) and/or thrombocytopenia
(platelets <50,000/mm3)
Biological [1 ] No  0= Absence of any of the following biological feature
Low  1= Clonal component and/or hypocomplementemia (low C4 or C3 or CH50) and/or hypergammaglobulinemia or high IgG level between 16 and 20 g/L
Moderate
 2=
Presence of cryoglobulinemia and/or hypergammaglobulinemia or high IgG level > 20 g/L, and/or recent onset hypogammaglobulinemia or recent
decrease of IgG level (<5 g/L)
CIDP  chronic inflammatory demyelinating polyneuropathy; CK  creatine kinase; CNS  central nervous system; DLCO  diffusing CO capacity; EMG  electromyogram; FVC  forced vital capacity;= = = = = =
GFR  glomerular filtration rate; Hb  hemoglobin; HRCT  high-resolution computed tomography; IgG  immunoglobulin G; NCS  nerve conduction studies; NHYA  New York heart association= = = = = =
classification; Plt  platelet; PNS peripheral nervous system;= =
